Emrich IE, et al. – In this study, researchers focused on the interplay between fibroblast growth factor 23 (FGF23), its non-chronic kidney disease (CKD)-mineral bone disease (MBD) regulators, and incident cardiovascular events in CKD patients in the CARE FOR HOMe study. Among 575 CKD G2-G4 patients, they analyzed plasma ferritin, intact FGF23 (iFGF23), c-terminal FGF23 (cFGF23), and N-terminal proBNP (NT-proBNP) along with conventional risk factors, with follow-up for 5.1 ± 2.1 years during which time the primary focus was the occurrence of atherosclerotic events and hospitalization for acute decompensated heart failure. Findings revealed an influence of iron deficiency and heart failure (recently discovered non-CKD-MBD regulators) on plasma FGF23. They hypothesized that high FGF23 may reflect prevalent heart disease, rather than exerting detrimental cardiovascular impacts, as the link between plasma FGF23 and predefined outcome was virtually eliminated by adjustment for NT-proBNP.